Medarex and GenPat77 Announce Therapeutic Antibody Co-Development Agreement

24-Aug-2006

Medarex, Inc. and GenPat77 Pharmacogenetics AG have entered into a collaborative agreement to develop fully human therapeutic antibody products. The companies plan to use Medarex's UltiMAb Human Antibody Development System® to generate antibodies to novel disease targets provided by GenPat77.

Under the terms of the agreement, Medarex and GenPat77 plan to share product development and commercialization responsibilities on any antibody products resulting from this collaboration. Other financial terms of the agreement were not disclosed.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous